Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jankistomig
- Development stage
- Preclinical
- Lead developer
- Ottimo Pharma
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous (anticipated Based On Modality)
01
Overview
Jankistomig is a novel, bi-functional bispecific antibody developed by Ottimo Pharma for the treatment of solid tumors. It is designed to simultaneously target and block both the programmed cell death protein 1 (PD1) immune checkpoint pathway and the vascular endothelial growth factor receptor 2 (VEGFR2) angiogenesis pathway in a single IgG molecule. By combining these mechanisms, Jankistomig aims to enhance anti-tumor immune responses while minimizing VEGF-related adverse effects through selective VEGFR2 targeting. The drug leverages high affinity for PD1 to improve tumor immune cell biodistribution and represents an innovative approach in cancer immunotherapy, with potential benefits across a wide range of solid tumors[1][3][4][5][6].
- Brand names
- Jankistomig
- Other names
- Jankistomig-Ottimo Pharma
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on Jankistomig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jankistomig.